Caliway Biopharmaceuticals Co., Ltd.
Taipei ExchangeTotal Valuation
Caliway Biopharmaceuticals Co., Ltd. carries a market capitalization of 15.34B, placing it among publicly traded companies globally. Its enterprise value stands at 72.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 15.34B |
| Enterprise Value | 72.13B |
Share Statistics
Caliway Biopharmaceuticals Co., Ltd. currently has 153.44M shares outstanding.
| Shares Outstanding | 153.44M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1,637.01, and the price-to-book ratio stands at 348.88.
| PE Ratio | N/A |
| PS Ratio | 1,637.01 |
| PB Ratio | 348.88 |
| P/TBV Ratio | 8.41 |
| P/FCF Ratio | -138.72 |
| P/OCF Ratio | -135.59 |
Enterprise Valuation
| EV / Sales | 1,443.32 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Caliway Biopharmaceuticals Co., Ltd. maintains a current ratio of 149.70, meaning it holds 149.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.14, indicating conservative leverage, while an interest coverage ratio of -1,873.12 demonstrates limited ability to service its debt obligations.
| Current Ratio | 149.70 |
| Quick Ratio | 149.15 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | -1,873.12 |
Financial Efficiency
| Return on Equity (ROE) | -555.22 |
| Return on Assets (ROA) | -13.28 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 10.34 |
Stock Price Statistics
Caliway Biopharmaceuticals Co., Ltd.'s stock has declined approximately -26.73993% over the past 52 weeks. The 50-day moving average sits at 99.87, while the 200-day moving average is 136.46.
| Beta (5Y) | N/A |
| 52-Week Price Change | -26.73993% |
| 50-Day Moving Average | 99.87 |
| 200-Day Moving Average | 136.46 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Caliway Biopharmaceuticals Co., Ltd. generated 49.98M in revenue and converted that into -651.00M in net income, yielding earnings per share of -4.68. EBITDA reached -700.55M, while operating income came in at -700.55M.
| Revenue | 49.98M |
| Gross Profit | 34.67M |
| Operating Income | -700.55M |
| Pretax Income | -651.00M |
| Net Income | -651.00M |
| EBITDA | -700.55M |
| EBIT | -700.55M |
| Earnings Per Share (EPS) | -4.68 |
Balance Sheet
Caliway Biopharmaceuticals Co., Ltd. holds 9.69B in cash and equivalents against 14.07M in total debt, resulting in a net debt position of -9.03B. Total book value stands at 234.50M, with working capital of 9.66B providing operational flexibility.
| Cash & Cash Equivalents | 9.69B |
| Total Debt | 14.07M |
| Net Debt | -9.03B |
| Equity (Book Value) | 234.50M |
| Book Value Per Share | 1.69 |
| Working Capital | 9.66B |
Cash Flow
Caliway Biopharmaceuticals Co., Ltd. produced -603.38M in operating cash flow over the past twelve months. After subtracting -13.59M in capital expenditures, free cash flow totaled -616.98M - equivalent to -4.43 per share.
| Operating Cash Flow | -603.38M |
| Capital Expenditures | -13.59M |
| Free Cash Flow | -616.98M |
| FCF Per Share | -4.43 |
Margins
Caliway Biopharmaceuticals Co., Ltd. operates with a gross margin of 69.37, reflecting its pricing power and cost economics. The operating margin of -1,401.74 and net profit margin of -1,302.60 provide insight into operational efficiency.
| Gross Margin | 69.37 |
| Operating Margin | -1,401.74 |
| Pretax Margin | -1,302.60 |
| Profit Margin | -1,302.60 |
| EBITDA Margin | -1,401.74 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -11.63 |
| FCF Yield | -0.72 |
Stock Splits
Caliway Biopharmaceuticals Co., Ltd.'s most recent stock split took place on March 29, 2024 with a 1:2 split ratio.
| Last Split Date | 3/29/2024 |
| Split Ratio | 1:2 |
Scores
Caliway Biopharmaceuticals Co., Ltd. posts an Altman Z-Score of 699.83, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 699.83 |